Table 1.
Summary of the Parkinson’s group and control group
| Parkinson’s patients | Healthy controls | |
|---|---|---|
| N | 19 | 19 |
| Sex | 5 females, 14 males | 8 females, 11 males |
| Age | 44–85 years (mean: 67.3 years) | 54–76 years (mean: 69.3 years) |
| Disease duration | 1–14 years (median: 4.5 years) | |
| LEDD | 300–1150 mg (median: 615 mg) | |
| MDS-UPDRS-III (non-medicated) | 10–61 (median: 34) | |
| MDS-UPDRS-III (medicated) | 5–39 (median: 16) | |
| MoCA | 25.5 (SD: 2.9) | 26.1 (SD: 1.8) |
LEDD = levodopa equivalent daily dosage; MDS-UPDRS-III = Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale part III; MoCA = Montreal Cognitive Assessment.